MYCN and neuroblastoma: In contrast, we found that pan-IAP antagonists tested in this study including LCL-161, CUDC-427, Debio1143, and BV6 targeted mainly c-IAPs, induced high toxicity in normal cells and were ineffective toward XIAP-dependent, MYCN-amplified neuroblastomas.